Compare Cardinal Health Inc (CAH) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Honeywell International Inc — how do they compare? Cardinal Health Inc trades at $229.02 (market cap $53.89B), while Honeywell International Inc trades at $222.42 (market cap $70.55B). The key difference: Honeywell International Inc is the larger of the two by market cap, and Honeywell International Inc pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| CAH | HON | |
|---|---|---|
Market Cap | $53.89B | $70.55B |
Sector | Health | Industrials |
52-Week High | $239.71 | $248.04 |
52-Week Low | $146.04 | $188.14 |
Enterprise Value | $58.87B | $94.90B |
Dividend Yield | 0.89% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
Honeywell (HON) trades at $222.25, down 1.84% on the day, with a bearish technical signal. The company reported strong recent earnings beats but faces near-term uncertainty from its Aerospace and Quantinuum spinoffs. Key financials show solid profitability with a 10.89% net margin and 26.41% ROE, though revenue declined slightly in 2025. A recent 2:1 reverse stock split and updated 2026 guidance aim to streamline operations. Analyst consensus remains strongly bullish with a $368.55 price target, but technical indicators suggest caution.
The outlook for HON hinges on successful execution post-spinoff and margin improvement targets. Investment opportunity lies in its focused automation and industrial technology portfolio, attractive valuation (P/E 17.75), and strong analyst support. Key risks include near-term earnings volatility, competitive pressures, and macroeconomic headwinds impacting industrial demand. The stock's current bearish technical trend warrants monitoring for stabilization above key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
